DE2134930A1 - Antigene Extrakte - Google Patents
Antigene ExtrakteInfo
- Publication number
- DE2134930A1 DE2134930A1 DE19712134930 DE2134930A DE2134930A1 DE 2134930 A1 DE2134930 A1 DE 2134930A1 DE 19712134930 DE19712134930 DE 19712134930 DE 2134930 A DE2134930 A DE 2134930A DE 2134930 A1 DE2134930 A1 DE 2134930A1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- protein
- material according
- species
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims description 11
- 230000000890 antigenic effect Effects 0.000 title description 3
- 239000000463 material Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 15
- 241000589567 Brucella abortus Species 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 229940056450 brucella abortus Drugs 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- -1 alkali metal salt Chemical class 0.000 claims description 3
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 3
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical group [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 241000589562 Brucella Species 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229940050271 potassium alum Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 13
- 230000004520 agglutination Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 206010000210 abortion Diseases 0.000 description 6
- 231100000176 abortion Toxicity 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010006500 Brucellosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000002337 glycosamines Chemical class 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010024769 Local reaction Diseases 0.000 description 3
- 230000004523 agglutinating effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 244000309465 heifer Species 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JUQLUIFNNFIIKC-UHFFFAOYSA-N 2-aminopimelic acid Chemical compound OC(=O)C(N)CCCCC(O)=O JUQLUIFNNFIIKC-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000252254 Catostomidae Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000970811 Dictyoglomi Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3445770 | 1970-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2134930A1 true DE2134930A1 (de) | 1972-01-20 |
Family
ID=10365885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712134930 Pending DE2134930A1 (de) | 1970-07-16 | 1971-07-13 | Antigene Extrakte |
Country Status (5)
| Country | Link |
|---|---|
| DE (1) | DE2134930A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2100920B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1352125A (enrdf_load_stackoverflow) |
| IE (1) | IE35396B1 (enrdf_load_stackoverflow) |
| NL (1) | NL7109451A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148877A (en) * | 1975-12-29 | 1979-04-10 | Choay S. A. | Fraction capable of inducing in vivo a resistance to bacterial infections, process for obtaining said fraction from bacteria and drugs containing said fraction |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2506615A1 (fr) * | 1981-06-01 | 1982-12-03 | Merieux Inst | Vaccin contre les brucelloses humaines et son procede de fabrication |
| FR2524315B1 (fr) * | 1982-04-02 | 1985-07-12 | Merieux Inst | Nouvel antigene pour la recherche de l'hypersensibilite cutanee brucellique notamment chez l'homme, et son procede de preparation |
| US5718903A (en) * | 1987-03-30 | 1998-02-17 | The Texas A&M University System | Vaccine comprising Brucella abortus which has O polysaccharide antigen absent |
| BR9305970A (pt) * | 1992-02-25 | 1997-10-21 | Texas A & M Univ Sys | Vacina aperfeiçoada contra brucella abortus |
-
1970
- 1970-07-16 GB GB1352125D patent/GB1352125A/en not_active Expired
-
1971
- 1971-06-24 IE IE81271A patent/IE35396B1/xx unknown
- 1971-07-08 NL NL7109451A patent/NL7109451A/xx unknown
- 1971-07-13 DE DE19712134930 patent/DE2134930A1/de active Pending
- 1971-07-15 FR FR7125920A patent/FR2100920B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148877A (en) * | 1975-12-29 | 1979-04-10 | Choay S. A. | Fraction capable of inducing in vivo a resistance to bacterial infections, process for obtaining said fraction from bacteria and drugs containing said fraction |
Also Published As
| Publication number | Publication date |
|---|---|
| NL7109451A (enrdf_load_stackoverflow) | 1972-01-18 |
| FR2100920A1 (enrdf_load_stackoverflow) | 1972-03-24 |
| GB1352125A (en) | 1974-05-08 |
| FR2100920B1 (enrdf_load_stackoverflow) | 1976-04-16 |
| IE35396L (en) | 1972-01-16 |
| IE35396B1 (en) | 1976-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69215355T2 (de) | Stabilisierter Varizella-Lebendimpfstoff | |
| DE2542792A1 (de) | Verfahren zur erhoehung der antikoerpermenge in der milch von milchabsondernden rindern | |
| DE69232969T2 (de) | Methode zur herstellung von gram-negativen bakteriellen vakzinen | |
| DE69432665T3 (de) | Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt | |
| DE3024282A1 (de) | Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen | |
| DE2134930A1 (de) | Antigene Extrakte | |
| DE2360118B2 (de) | Impfstoff gegen Ferkel-Colibacillose | |
| DE4007315A1 (de) | Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen | |
| DE1492243C3 (de) | Injizierbare Impfstoffe | |
| DE69231724T2 (de) | Fischimpfstoff gegen infektion mit aeromonas salmonicida | |
| DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
| DE3878982T2 (de) | Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus. | |
| DE2141901C3 (de) | Steriler Impfstoff, der abgetötete Organismen des genus Fusiformis nodosus enthält | |
| DE3005495C2 (de) | Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen | |
| DE2214229A1 (de) | Impfstoffpräparat mit Adjuvans | |
| DE2728806A1 (de) | Auf oralem wege einzunehmender antiparasitaerer impfstoff, verfahren zu dessen herstellung und anwendungsmethode des impfstoffs bei saeugetieren | |
| DE69130953T2 (de) | Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie | |
| DE1902590C2 (de) | Verwendung einer Immunribonucleinsäure (IRNS) zum Immunisieren lebender Tiere | |
| DE908909C (de) | Verfahren zur Herstellung und Verarbeitung pathogener Viren und der sie begleitenden Stoffe | |
| DE3028248A1 (de) | Emulgierte antigenzubereitung aus bacteroides nodosus und aluminiumadjuvans und ihre verwendung als impfstoff | |
| DE2162013C3 (de) | Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut | |
| DE2644149C3 (de) | Neue Parasiten-Antigene | |
| DE1467817A1 (de) | Verfahren zur Herstellung von Vaccinen | |
| DE1253412B (de) | Verfahren zur Gewinnung eines Impfstoffes gegen infektioese Schweinegastroenteritis | |
| DE3779444T2 (de) | Impfstoff gegen herpes simplex. |